Browsing Tag
Blueprint Medicines Corporation
2 posts
Blueprint Medicines highlights long-term clinical and real-world data for Ayvakit at EHA and EAACI 2025
Blueprint Medicines presents strong long-term survival and safety data for Ayvakit in systemic mastocytosis at EHA and EAACI 2025. Explore the clinical and market impact.
U.S. stock market gainers surge amid AI boom, infrastructure bets, and rate cut expectations
Find out how top-performing U.S. stocks like MYR Group, TTM Technologies, and Quanta Services are surging amid AI tailwinds, infrastructure bets, and macro shifts.